Project Number 5P01AG022074-07 Agency/Funding Organization NIA Funding Year 2009 View Full Project Details for MECHANISMS OF AB-INDUCED NEURONAL DEFICITS Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 1. Amyloid beta g. Amyloid beta-Mediated Pathogenesis Researcher and Organization Principal Investigator MUCKE, LENNART Principal Investigator First Name LENNART Principal Investigator Last Name MUCKE Awardee Organization J. DAVID GLADSTONE INSTITUTES Awardee State California Contact PI Country United States Project Detail FY Overall Cost $390,631 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official REFOLO, LORENZO Related Resources Repository [AlzPED] Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease [AlzPED] Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis [AlzPED] Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model [AlzPED] Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model [AlzPED] Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease. [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.